Artivion/$AORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Ticker
$AORT
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
1,600
ISIN
US2289031005
Website
Artivion Metrics
BasicAdvanced
$1.4B
-
-$0.53
1.54
-
Price and volume
Market cap
$1.4B
Beta
1.54
52-week high
$32.33
52-week low
$21.97
Average daily volume
366K
Financial strength
Current ratio
5.531
Quick ratio
2.569
Long term debt to equity
121.318
Total debt to equity
123.146
Interest coverage (TTM)
0.57%
Profitability
EBITDA (TTM)
43.169
Gross margin (TTM)
63.94%
Net profit margin (TTM)
-5.49%
Operating margin (TTM)
4.98%
Effective tax rate (TTM)
5.28%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
1.54%
Return on equity (TTM)
-7.26%
Valuation
Price to revenue (TTM)
3.191
Price to book
4.31
Price to tangible book (TTM)
-11.87
Price to free cash flow (TTM)
-71.379
Free cash flow yield (TTM)
-1.40%
Free cash flow per share (TTM)
-41.61%
Growth
Revenue change (TTM)
5.94%
Earnings per share change (TTM)
126.44%
3-year revenue growth (CAGR)
8.55%
10-year revenue growth (CAGR)
10.58%
3-year earnings per share growth (CAGR)
11.81%
10-year earnings per share growth (CAGR)
9.97%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Bulls say / Bears say
Artivion's recent clinical trials, such as the NEXUS TRIOMPHE IDE Trial, demonstrated a 63% reduction in major adverse events, potentially enhancing product adoption and revenue growth. (Artivion News Release)
The company secured $350 million in senior secured credit facilities, providing financial flexibility to address debt maturities and invest in growth initiatives. (PR Newswire)
Artivion reported a 4% year-over-year revenue increase in Q4 2024, indicating steady growth in its core business segments. (Zacks)
Artivion's Q4 2024 earnings missed analyst expectations, reporting break-even EPS versus the anticipated $0.12, raising concerns about profitability. (Zacks)
The company's significant debt load, with net debt of approximately $260.9 million as of December 2024, poses financial risks and potential constraints on future operations. (AInvest)
Artivion's stock valuation appears stretched, with recent share price increases potentially outpacing fundamental growth, leading to concerns about overvaluation. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Artivion stock?
Artivion (AORT) has a market cap of $1.4B as of June 20, 2025.
What is the P/E ratio for Artivion stock?
The price to earnings (P/E) ratio for Artivion (AORT) stock is 0 as of June 20, 2025.
Does Artivion stock pay dividends?
No, Artivion (AORT) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Artivion dividend payment date?
Artivion (AORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Artivion?
Artivion (AORT) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.